Patents by Inventor Roy H. Larsen

Roy H. Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SIZE CONTROLLED RADIOLABELLED PARTICLES
    Publication number: 20230372554
    Abstract: The present disclosure relates to a particle comprising a degradable compound, a radionuclide, and a phosphorus containing additive. Phosphorus containing additives, such as phosphonates, have the unique ability to control the size of particles for medical applications. The applications allow for use of the particles as medicaments and for imaging, especially within the field of cancer.
    Type: Application
    Filed: September 15, 2021
    Publication date: November 23, 2023
    Inventors: Roy H. Larsen, Tina B. Bønsdorff
  • PRODUCTION OF HIGHLY PURIFIED 212PB
    Publication number: 20230014219
    Abstract: The present invention relates to assemblies and method for obtaining a container comprising 212Pb on the walls obtained from a 212Pb precursor isotope source. The invention provides an improved system and method for producing 212Pb high purity without the need for processing, with high yields, and which safely and efficiently can be transported to the locations where it is to be used.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 19, 2023
    Inventor: Roy H. Larsen
  • Method for upregulating antigen expression
    Patent number: 10646599
    Abstract: The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 12, 2020
    Assignee: NORDIC NANOVECTOR ASA
    Inventors: Roy H. Larsen, Ada Repetto-Llamazares
  • METHOD FOR UPREGULATING ANTIGEN EXPRESSION
    Publication number: 20190008989
    Abstract: The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.
    Type: Application
    Filed: June 13, 2018
    Publication date: January 10, 2019
    Inventors: Roy H. Larsen, Ada Repetto-Llamazares
  • CHIMERIC THERAPEUTIC ANTI - CD37 ANTIBODIE HH1
    Publication number: 20180194852
    Abstract: The present invention relates to chimeric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies.
    Type: Application
    Filed: December 19, 2017
    Publication date: July 12, 2018
    Inventors: Roy H. Larsen, Jostein Dahle
  • Radioimunoconjugates and uses thereof
    Patent number: 9358309
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer and in particular B cell malignancies are aspects of the present invention.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: June 7, 2016
    Assignee: Nordic Nanovector AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S. Bruland
  • METHOD FOR UPREGULATING ANTIGEN EXPRESSION
    Publication number: 20160101199
    Abstract: The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.
    Type: Application
    Filed: June 6, 2014
    Publication date: April 14, 2016
    Inventors: Roy H. Larsen, Ada Repetto-Llamazares
  • RECEPTOR BINDING CONJUGATES
    Publication number: 20150258223
    Abstract: The present invention relates to a receptor binding conjugate which consists of an antibody, a radionuclide and folate or a folate derivative, wherein or not the conjugate possesses dual binding ability. The present invention also relates to a method and a kit to prepare, as well as a method to use, such conjugates. Furthermore, the use of a conjugate according to the present invention to prepare a pharmaceutical solution is disclosed.
    Type: Application
    Filed: December 16, 2014
    Publication date: September 17, 2015
    Inventors: Roy H. LARSEN, Gjermund HENRIKSON
  • CHIMERIC THERAPEUTIC ANTI - CD37 ANTIBODIE HH1
    Publication number: 20140348745
    Abstract: The present invention relates to chimieric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 27, 2014
    Inventors: Roy H. Larsen, Jostein Dahle
  • METHOD OF RADIOTHERAPY
    Publication number: 20140235924
    Abstract: The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such that an acceptably non-myelotoxic quantity of radium-223 is generated in vivo by nuclear decay of the administered thorium-227.
    Type: Application
    Filed: February 19, 2014
    Publication date: August 21, 2014
    Applicant: Algeta ASA
    Inventors: Roy H. LARSEN, Oyvind S. BRULAND
  • RADIOIMMUNOCONJUGATES AND USES THEREOF
    Publication number: 20140147384
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer and in particular B cell malignancies are aspects of the present invention.
    Type: Application
    Filed: December 9, 2013
    Publication date: May 29, 2014
    Applicant: Nordic Nanovector AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S. Bruland
  • Radioimmunoconjugates and uses thereof
    Patent number: 8628749
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer—and in particular B-cell malignancies—are aspects of the present invention.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: January 14, 2014
    Assignee: Nordic Nanovector AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S Bruland
  • RADIOIMMUNOCONJUGATES AND USES THEREOF
    Publication number: 20120301396
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer—and in particular B-cell malignancies—are aspects of the present invention.
    Type: Application
    Filed: January 28, 2011
    Publication date: November 29, 2012
    Applicant: NORDIC NANOVECTOR AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S. Bruland
  • Alpha-emitting hydroxyapatite particles
    Patent number: 8142758
    Abstract: The present invention provides Hydroxyapatite (HA) incorporating an alpha-emitting radionuclide or an in vivo generator for an alpha-emitting radionuclide. The invention further provides methods for the formation of such HA, pharmaceutical compositions comprising the HA and methods of medical treatment of cancerous or noncancerous disease including administering the HA or compositions thereof.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: March 27, 2012
    Assignee: Algeta AS
    Inventors: Roy H. Larsen, Gro Salberg
  • Alpha-Emitting Hydroxyapatite Particles
    Publication number: 20080226547
    Abstract: The present invention provides Hydroxyapatite (HA) incorporating an alpha-emitting radionuclide or an in vivo generator for an alpha-emitting radionuclide. The invention further provides methods for the formation of such HA, pharmaceutical compositions comprising the HA and methods of medical treatment of cancerous or noncancerous disease including administering the HA or compositions thereof.
    Type: Application
    Filed: February 18, 2005
    Publication date: September 18, 2008
    Inventors: Roy H. Larsen, Gro Salberg
  • Method of radiotherapy
    Publication number: 20040208821
    Abstract: The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such that an acceptably non-myelotoxic quantity of radium-223 is generated in vivo by nuclear decay of the administered thorium-227.
    Type: Application
    Filed: April 23, 2003
    Publication date: October 21, 2004
    Inventors: Roy H. Larsen, Oyvind S. Bruland
  • Receptor binding conjugates
    Publication number: 20040184990
    Abstract: The present invention relates to a receptor binding conjugate which consists of an antibody, a radionuclide and folate or a folate derivative, wherein or not the conjugate possesses dual binding ability. The present invention also relates to a method and a kit to prepare, as well as a method to use, such conjugates. Furthermore, the use of a conjugate according to the present invention to prepare a pharmaceutical solution is disclosed.
    Type: Application
    Filed: January 28, 2004
    Publication date: September 23, 2004
    Inventors: Roy H. Larsen, Gjermund Henriksen
  • Receptor binding conjugates
    Patent number: 6740304
    Abstract: The present invention relates to a receptor binding conjugate which consists of an antibody, a radionuclide and folate or a folate derivative, wherein or not the conjugate possesses dual binding ability. The present invention also relates to a method and a kit to prepare, as well as a method to use, such conjugates. Furthermore, the use of a conjugate according to the present invention to prepare a pharmaceutical solution is disclosed.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: May 25, 2004
    Assignee: Anticancer Therapeutic Inventions AS
    Inventors: Roy H. Larsen, Gjermund Henriksen
  • Method of prophylaxis
    Publication number: 20040009955
    Abstract: A method of prophylaxis of a subject having or having had a soft tissue cancer, whereby to combat metastatic bone cancer therein, the method comprising administering to said subject a physiologically tolerable polyphosphonate and, parenterally, a prophylactically effective amount of a soluble radium-223 or -224 salt or complex. A kit comprising a first container containing a soluble radium-223 or -224 salt or complex and a second container containing at least one dose of a physiologically tolerable polyphosphonate is also provided.
    Type: Application
    Filed: May 30, 2003
    Publication date: January 15, 2004
    Inventors: Roy H. Larsen, Oyvind S. Bruland
  • Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
    Publication number: 20030206857
    Abstract: Processes for the preparation, prepared solutions, and the use of radium-223 for the treatment of calcified tumors, bone tumors, treatment of bones, bone surfaces and soft tissues is described.
    Type: Application
    Filed: June 12, 2003
    Publication date: November 6, 2003
    Inventors: Roy H. Larsen, Gjermund Henriksen, Oyvind S. Bruland